Knee treatment choices work best as part of a larger plan

Exercise and suitable medicines remain useful

Regular exercise can help an arthritic knee, though a bad flare may call for a lighter day. Losing some weight may ease strain when extra weight is part of the trouble. You might also try a gel on the skin or a pill. You don’t have to do everything at once.

Pills aren’t harmless for everyone. Kidney, heart, and stomach concerns may rule some of them out. Ask the person who knows your health before starting one. The useful question is simple: which safe choice could help you move more?

Cortisone tends to help sooner than it helps longer

Cortisone often helps most during the first few weeks. By roughly three months, relief is usually smaller. When researchers put several studies together, they couldn’t show that it was still helping at six months. A shorter spell of relief can still matter to you.

Repeated cortisone deserves care. One two-year trial compared regular cortisone with salt water that had no medicine in it. The cortisone group lost more cartilage, but their pain wasn’t better. Research doesn’t settle every question, so ask when another shot would no longer make sense.

Gel and blood-based care come with real uncertainty

Across many studies, gel beat a pretend treatment by too little for most patients to feel. Some people still say it helped them. The studies can’t tell us your personal chance of relief beforehand. Cost and coverage matter when the expected change is small.

QC Kinetix calls its non-surgical treatments made with material from your own body biologic therapies. One is platelet-rich plasma (PRP). After drawing blood, the team spins it to collect a small portion rich in platelets, then puts that portion into the knee through a needle. Some studies found more relief with PRP, but in one large trial it worked no better than salt water without medicine at 12 months.

Ultrasound helps place the needle, but relief isn’t certain

An ultrasound picture lets the person doing the procedure watch the needle enter your knee joint. It can also show fluid that may need to be drawn and checked. This helps with placement, but it can’t prove the medicine will help months later. Ask why ultrasound is useful for your knee.

Surgery remains a sound choice for some severe knee trouble. It isn’t a failure, and non-surgical care won’t always replace it. Waiting, continuing exercise, or asking a surgeon for an opinion may all be reasonable. No choice fits everyone.

Sources

1. The 2015 Cochrane review of 27 trials (1,767 participants) found intra-articular corticosteroid better than sham for knee OA pain (SMD -0.40, 95% CI -0.58 to -0.22; NNTB 8), but the benefit decayed with time: moderate at 1-2 weeks, small at 13 weeks, and no evidence of any effect at 26 weeks. All outcomes were graded LOW quality.

   Jüni P, et al. — Intra-articular corticosteroid for knee osteoarthritis.. Cochrane Database Syst Rev, 2015. DOI: 10.1002/14651858.CD005328.pub3.

2. A 2022 BMJ systematic review and meta-analysis of 169 trials (21,163 participants) found viscosupplementation produced only a small pain reduction versus placebo (SMD -0.08, 95% CI -0.15 to -0.02; about -2.0 mm on a 100 mm VAS), below the minimal clinically important difference, and trial sequential analysis indicated conclusive evidence of clinical equivalence with placebo since 2009.

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

3. The RESTORE randomized trial (288 participants, leukocyte-poor PRP, 3 weekly injections) found no significant difference from saline placebo at 12 months in knee pain (-2.1 vs -1.8 points; difference -0.4, 95% CI -0.9 to 0.2) or in medial tibial cartilage volume (-1.4% vs -1.2%), with 29 of 31 secondary outcomes also showing no between-group difference.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

4. The 2025 Cochrane living review of stem cell injections for knee OA (25 trials, 1,341 participants) found stem cell injection MAY slightly improve pain and function up to six months versus placebo (pain 1.2 points better on a 0-10 scale; function 14.2 points better on 0-100), but rated the evidence LOW certainty for both, downgraded for indirectness and suspected publication bias, with up to three larger RCTs withdrawn before reporting results.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database Syst Rev, 2025. DOI: 10.1002/14651858.CD013342.pub2.

5. FDA's HCT/P guidance sets out the minimal-manipulation and homologous-use criteria that decide whether a human cell or tissue product is regulated solely under 21 CFR Part 1271 (section 361) or requires a biologics licence; cell-based orthopaedic injections that fall outside those criteria are unapproved drugs and biological products, and no cell-based product is FDA-approved to treat osteoarthritis.

   U.S. Food and Drug Administration — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and FDA Staff. U.S. Food and Drug Administration, 2020.

6. The AAOS third-edition non-arthroplasty knee OA guideline (2022) issues 29 recommendations across non-pharmacologic and pharmacologic care, and its work group explicitly flagged the need for better research on intra-articular corticosteroid, hyaluronic acid and platelet-rich plasma.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. J Am Acad Orthop Surg, 2022. DOI: 10.5435/JAAOS-D-21-01233.